Comments
Loading...
Telomir Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:TELO | Benzinga
Telomir Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 4
EPS
$-0.080
Quarterly Revenue
$0.00
Annual Revenue
(as of Dec 31)
(as of Dec 31)
–
Analyze the earnings history of Telomir Pharmaceuticals using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals | -$0.23 | — | — | — | $0.00 | — | — | — | 05/12/2025 | Get Alert |
| TELO | Telomir Pharmaceuticals | — | — | -$0.08 | — | — | — | $0.00 | — | 02/04/2025 | Get Alert |
| TELO | Telomir Pharmaceuticals | -$0.06 | — | -$0.20 | — | — | — | $0.00 | — | 11/12/2024 | Get Alert |
| TELO | Telomir Pharmaceuticals | -$0.06 | — | -$0.05 | — | — | — | $0.00 | — | 08/13/2024 | Get Alert |
| TELO | Telomir Pharmaceuticals | -$0.02 | — | -$0.23 | — | $0.00 | — | $0.00 | — | 05/13/2024 | Get Alert |
Telomir Pharmaceuticals (TELO) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
Telomir Pharmaceuticals (TELO) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Telomir Pharmaceuticals (NASDAQ:TELO) reporting earnings?
Telomir Pharmaceuticals (TELO) is scheduled to report earnings on May 12, 2025. The last reported earnings were for reported on February 4, 2025 for Q4.
What were the latest earnings per share (EPS) for Telomir Pharmaceuticals (NASDAQ:TELO)?
The Actual EPS was $-0.08, which missed the estimate of $0.00.
What were Telomir Pharmaceuticals’s (NASDAQ:TELO) revenues?
The Actual Revenue was $0K, which hit the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.